Lapatinib or trastuzumab? Which anti-HER2 treatment is more effective in the treatment of patients with HER2-positive breast cancer with brain metastases? An Anatolian Society of Medical Oncology Study

Kaplan, Muhammet AliIsikdogan, AbdurrahmanKoca, DoganKucukoner, MehmetGumusay, OzgeYildiz, RamazanOztop, Ilhan2024-04-242024-04-2420120732-183X1527-7755https://hdl.handle.net/11468/2313248th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 01-06, 2012 -- Chicago, IL[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keyword]Lapatinib or trastuzumab? Which anti-HER2 treatment is more effective in the treatment of patients with HER2-positive breast cancer with brain metastases? An Anatolian Society of Medical Oncology StudyLapatinib or trastuzumab? Which anti-HER2 treatment is more effective in the treatment of patients with HER2-positive breast cancer with brain metastases? An Anatolian Society of Medical Oncology StudyConference Object3015WOS:000318009800398Q1